Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2025)

Caris Life Sciences has reported Total Non-Current Liabilities over the past 2 years, most recently at $506.0 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $506.0 million for Q4 2025, down 12.23% from a year ago — trailing twelve months through Dec 2025 was $506.0 million (down 12.23% YoY), and the annual figure for FY2025 was $506.0 million, down 12.23%.
  • Total Non-Current Liabilities for Q4 2025 was $506.0 million at Caris Life Sciences, roughly flat from $506.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CAI hit a ceiling of $576.5 million in Q4 2024 and a floor of $502.2 million in Q2 2025.